

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

October 15, 1993

V John Dallan

<u>PATENT</u>

Attorney Docket No. 16243-1-5

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)
Richard H. Tullis	) Examiner: Martinell
Serial No.: 08/078,767	) Art Unit: 1805
Filed: June 16, 1993	PRELIMINARY AMENDMENT
For: OLIGONUCLEOTIDE THERAPEUTIC AGENT AND METHODS OF MAKING SAME	} }
	- RECEIVED

OCT 2 5 1993

GROUP 1800

Sir:

Applicant submits the enclosed remarks and amendments. An Information Disclosure Statement with attached PTO 1449 form is enclosed with references cited in a European opposition involving a granted application corresponding to the pending application.

**IN THE CLAIMS:** 

Please cancel claims 53-61 and 63.

Commissioner of Patents and Trademarks

Please add claims 64 - 72:

Washington, D.C. 20231

--64. A method of selectively inhibiting the expression of a target protein in a cell producing messenger ribonucleic acids encoding the target protein and other proteins without inhibiting the expression of the other proteins, said method comprising the steps of:

7